Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6:580–92. https://doi.org/10.1016/j.trecan.2020.02.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalmykova A, Buzdin A. Evolution of epigenetic mechanisms and signatures. Cells. 2022;12:109 https://doi.org/10.3390/cells12010109

Article  PubMed  PubMed Central  Google Scholar 

Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, et al. BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep. 2018;22:796–808. https://doi.org/10.1016/j.celrep.2017.12.078

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang W, Zheng X, Yang Y, Wang X, Shen Z. An overview on small molecule inhibitors of BRD4. Mini Rev Med Chem. 2016;16:1403–14. https://doi.org/10.2174/1389557516666160611014130

Article  CAS  PubMed  Google Scholar 

Vollmuth F, Blankenfeldt W, Geyer M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J Biol Chem. 2009;284:36547–56. https://doi.org/10.1074/jbc.M109.033712

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, et al. Drug discovery targeting bromodomain-containing protein 4. J Med Chem. 2017;60:4533–58. https://doi.org/10.1021/acs.jmedchem.6b01761

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donati B, Lorenzini E, Ciarrocchi A. BRD4 and cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164 https://doi.org/10.1186/s12943-018-0915-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanno T, Kanno Y, Siegel RM, Jang MK, Lenardo MJ, Ozato K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol Cell. 2004;13:33–43. https://doi.org/10.1016/s1097-2765(03)00482-9

Article  CAS  PubMed  Google Scholar 

Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728–36. https://doi.org/10.1016/j.molcel.2014.05.016

Article  CAS  PubMed  Google Scholar 

Liang Y, Tian J, Wu T. BRD4 in physiology and pathology: “BET” on its partners. Bioessays. 2021;43:e2100180 https://doi.org/10.1002/bies.202100180

Article  PubMed  Google Scholar 

Zhang M, Li Y, Zhang Z, Zhang X, Wang W, Song X, et al. BRD4 protein as a target for lung cancer and hematological cancer therapy: a review. Curr Drug Targets. 2023;24:1079–92. https://doi.org/10.2174/1389557516666160611014130

Article  CAS  PubMed  Google Scholar 

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73. https://doi.org/10.1038/nature09504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119–23. https://doi.org/10.1038/nature09589

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, et al. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J Med Chem. 2017;60:8369–84. https://doi.org/10.1021/acs.jmedchem.7b00746

Article  CAS  PubMed  Google Scholar 

Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA. 2013;110:19754–9. https://doi.org/10.1073/pnas.1310658110

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bechter O, Schoffski P. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors. Pharmacol Ther. 2020;208:107479 https://doi.org/10.1016/j.pharmthera.2020.107479

Article  CAS  PubMed  Google Scholar 

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413–7. https://doi.org/10.1038/nature16508

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3:e196–204. https://doi.org/10.1016/S2352-3026(16)00021-1

Article  PubMed  Google Scholar 

Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin Cancer Res. 2019;25:6309–19. https://doi.org/10.1158/1078-0432.CCR-19-0578

Article  CAS  PubMed  Google Scholar 

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6:492–500. https://doi.org/10.1158/2159-8290.CD-15-1335

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33:1582–614. https://doi.org/10.1016/j.biotechadv.2015.08.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Li Y, Zhang J, Zhang M, Wei A, Liu H, et al. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. Eur J Med Chem. 2021;209:112868 https://doi.org/10.1016/j.ejmech.2020.112868

Article  CAS  PubMed  Google Scholar 

Hu J, Wang Y, Li Y, Cao D, Xu L, Song S, et al. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. Eur J Med Chem. 2018;150:156–75. https://doi.org/10.1016/j.ejmech.2018.02.070

Article  CAS  PubMed  Google Scholar 

Li Z, Xiao S, Yang Y, Chen C, Lu T, Chen Z, et al. Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as highly potent and selective bromodomain and extra-terminal (BET) bromodomain inhibitors. J Med Chem. 2020;63:3956–75. https://doi.org/10.1021/acs.jmedchem.9b01784

Article  CAS  PubMed  Google Scholar 

Ran X, Zhao Y, Liu L, Bai L, Yang CY, Zhou B, et al. Structure-based design of gamma-carboline analogues as potent and specific BET bromodomain inhibitors. J Med Chem. 2015;58:4927–39. https://doi.org/10.1021/acs.jmedchem.5b00613

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Cao D, Chen T, Wang Y, Miao Z, Xu Y, et al. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J Med Chem. 2013;56:3833–51. https://doi.org/10.1021/jm301793a

Article  CAS  PubMed